Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Key Points: Novel, more potent codon-optimized human FVIII variant (codop-hFVIII-V3). Codop-hFVIII-V3 is safe and efficacious in mice and nonhuman primates, thus improving the prospects of gene therapy for hemophilia A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion
Malhotra, J. D., Miao, H., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S. W., & Kaufman, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809677105 · Cited by 673
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593
Self-citationCodon usage limitation in the expression of HIV-1 envelope glycoprotein
Haas, J., Park, E.-C., & Seed, B. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00482-7 · Cited by 532
Nathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
Self-citationNonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients with Severe Hemophilia A
Roth, D. A., Tawa, N. E., O'Brien, J. M., Treco, D. A., & Selden, R. F. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442301 · Cited by 364
Nathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Self-citationToole, J. J., Pittman, D. D., Orr, E. C., Murtha, P., Wasley, L. C., & Kaufman, R. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.16.5939 · Cited by 311
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“Notably, the designing of a codon-optimized, engineered version of FVIII has achieved the therapeutic levels of transgene expression that justified the clinical development of a gene therapy for hemophilia A.(106,107,144)”
BackgroundSelf-citationAdeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“A single trial is using an alternative BDD-FVIII, FVIII-V3, wherein 6 additional N-linked glycosylation sites were added to the SQ linker to improve expression.(154,191) HB trials have universally adapted the FIX-Padua (FIX-R338L) transgene, which affords 8-fold greater specific activity relative to wildtype FIX.”
MethodAAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
The past and future of haemophilia: diagnosis, treatments, and its complications
Peyvandi, F., Garagiola, I., & Young, G. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01123-x · Cited by 505
Metadata
- Authors
- McIntosh, J., Lenting, P. J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E. G. D., Christophe, O. D., McVey, J. H., Waddington, S., Nienhuis, A. W., Gray, J. T., Fagone, P., Mingozzi, F., Zhou, S.-Z., High, K. A., Cancio, M., Ng, C. Y. C., Zhou, J., Morton, C. L., Davidoff, A. M., & Nathwani, A. C.
- Affiliations
- National Health Service (GB)
- Université Paris-Sud (FR)
- University College London (GB)
- The Royal Free Hospital (GB)
- King's College London (GB)
- St. Jude Children's Research Hospital (US)
- Cellular Therapeutics (United Kingdom) (GB)
- Center for Cellular and Molecular Therapeutics and
- Children's Hospital of Philadelphia (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-04-25
- Volume
- 121
- Issue
- 17
- Pages
- 3335-3344
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3637010
- OpenAlex
- W1991453997
- Cited by
- 278
- References
- 43
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 12 · 2023: 17 · 2022: 29 · 2021: 20 · 2020: 30 · 2019: 15 · 2018: 27 · 2017: 18 · 2016: 30 · 2015: 21 · 2014: 17 · 2013: 11
- FWCI
- 18.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL094396, R01HL094396, R01HL073838)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia A, recombinant adeno-associated virus vectors, codon optimization, glycosylation, neutralizing antibodies, immunosuppression
- MeSH terms
- Dependovirus, Animals, Factor VIII, Genetic Vectors, Glycosylation, Hemophilia A, Humans, Immune Tolerance, Liver, Macaca mulatta, Male, Mice, Inbred C57BL, Peptide Fragments, Promoter Regions, Genetic, Genetic Variation, Blotting, Western, Genetic Therapy, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. https://app.cochat.ai/papers/10.1182/blood-2012-10-462200
- The paper
- McIntosh, J., Lenting, P. J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E. G. D., Christophe, O. D., McVey, J. H., Waddington, S., Nienhuis, A. W., Gray, J. T., Fagone, P., Mingozzi, F., Zhou, S.-Z., High, K. A., Cancio, M., Ng, C. Y. C., . . . Nathwani, A. C. (2013). Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. https://doi.org/10.1182/blood-2012-10-462200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.